HealthXL Global Gathering Chicago

Business Models in Digital Health

‍

Significant advancements have been made in working out novel business models for digital health products, but implementing a successful go-to-market strategy remains a major challenge.

We have seen a lot of trial and error, as well as migration between commercialization pathways. One of the critical crossroads on that pathway is whether companies should take the approach of delivering a service, a product, or a bit of both?

Each has pros and cons. A number of digital health products take a service approach, while traditional prescriptions are a product, which adds a layer of complexity to getting these to market.

At HealthXL’s next Global Gathering in Chicago, startups, pharma, and investors will break down the issues around the different approaches to getting a digital health product to market. ‍

‍

We will split up into several roundtables, with each tackling one of the following topics:

‍

(1) Development/Co-development

• Example use case: BrightInsight+ UCB built a disease management platform for patients with Myasthenia Gravis.
• Given the high investment and complexities with developing and managing a Digital Health solution internally, is risk-sharing with a manufacturer the better approach?

‍

(2) Joint Venture

• Example use case: K Health, Anthem and Blackstone Growth are teaming up to launch a joint venture that aims to lower healthcare costs and make care more accessible.
• What is the best way to structure a multi-modal partnership for greatest impact?

‍

(3) License

• Example use case: Biogen uses Twill's COPA product to support its patients with Multiple Sclerosis
• Is exclusivity and scale a challenge with licensing? Should pharma consider exclusive licensing only ?

‍

‍

‍

‍

‍